NK Cells +/− Atezolizumab for Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment using modified immune cells from umbilical cord blood to fight advanced lung cancer that didn't respond to previous treatments. Some patients will also receive a drug that boosts the immune system's ability to attack cancer. The goal is to find the best dose and see if the treatment is safe and effective.
Will I have to stop taking my current medications?
The trial requires that you have not received chemotherapy, radiation therapy, biological therapy, or immunotherapy within 21 days before starting the study treatment. It does not specify other medications, so you should discuss your current medications with the study team.
Is atezolizumab safe for humans?
How is the treatment with NK Cells and Atezolizumab unique for lung cancer?
This treatment combines NK cells (natural killer cells, which are part of the immune system that can attack cancer cells) with Atezolizumab, a drug that helps the immune system recognize and fight cancer by blocking a protein called PD-L1. This combination aims to enhance the body's immune response against lung cancer, offering a novel approach compared to traditional chemotherapy.14678
What data supports the effectiveness of the drug Atezolizumab for lung cancer?
Who Is on the Research Team?
Stephen Forman, MD
Principal Investigator
City of Hope Medical Center
Are You a Good Fit for This Trial?
Adults with advanced non-small cell lung cancer that has worsened after treatment with PD-1/PD-L1 inhibitors. They must not have HIV, active hepatitis B or C, and should have normal organ function. Pregnant or breastfeeding women can't join, nor can those with certain mutations in their tumors unless specific treatments failed.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Lymphodepletion
Patients receive fludarabine and cyclophosphamide intravenously to prepare for COH06 infusion
Treatment
Patients receive COH06 infusions on days 0, 7, 14, and 21. Patients at dose level 4 also receive atezolizumab on days 0, 14, 28, and 42
Follow-up
Participants are monitored for safety and effectiveness after treatment completion
What Are the Treatments Tested in This Trial?
Interventions
- Atezolizumab
- COH06
Find a Clinic Near You
Who Is Running the Clinical Trial?
City of Hope Medical Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator
CytoImmune Therapeutics
Collaborator